Ask AI
ProCE Banner Activity

ADCs with Alternative HER2 Targeting Mechanisms and Beyond HER2-Positive Disease: Expanding Potential Benefit to Other Breast Cancer Subsets

Slideset

Download this slideset to review the latest data on new directions using antibody drug conjugates in HER2-positive breast cancer and beyond.

Released: October 30, 2020

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Javier Cortes, MD, PhD

International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group
Barcelona, Spain
IOB Madrid, Institute of Oncology, Hospital Beata Maria Ana
Madrid, Spain

Javier Cortes, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, Bioasis, Biocon, BioInvent, BioNTech, Bliss, Boehringer Ingelheim, BridgeBio, Circle, Clovis Oncology, Daiichi Sankyo, Delcath Systems, Ellipses, Expres2ion, GEMoab, Gilead, Hexagon, Hibercell, Jazz, Leuko, Lilly, Menarini, Merck Sharp & Dohme, Reveal Genomics, Roche, Scorpion, Seattle Genetics, Zymeworks; honoraria: Astrazeneca, Daiichi Sankyo, Eisai, Gilead, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline, Zuellig; researcher: Ariad, AstraZeneca, Baxalta/Servier Affaires, Bayer Healthcare, Eisai, F. Hoffmann-La Roche, Guardant, Iqvia, Merck Sharp & Dohme, Pfizer, Piqur, Roche; individual publicly traded stocks and stock options: Leuko; travel/accommodation/expense: AstraZeneca, Daiichi Sankyo, Eisai, Gilead, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Stemline; royalties or patent beneficiary: Pharmaceutical Combinations of a PI3K Inhibitor and a Microtubule Destabilizing Agent (issued); HER2 as a Predictor of Response to Dual HER2 Blockade (licensed).